Cargando…

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

Detalles Bibliográficos
Autores principales:	Dummer, Reinhard, Daud, Adil, Puzanov, Igor, Hamid, Omid, Schadendorf, Dirk, Robert, Caroline, Schachter, Jacob, Pavlick, Anna, Gonzalez, Rene, Hodi, F Stephen, Cranmer, Lee D, Blank, Christian, O’Day, Steven J, Ascierto, Paolo A, Salama, April K S, Li, Nicole Xiaoyun, Zhou, Wei, Lis, Joy, Ebbinghaus, Scot, Kang, Peter S, Ribas, Antoni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315269/ http://dx.doi.org/10.1186/1479-5876-13-S1-O5

Ejemplares similares

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
por: Hamid, Omid, et al.
Publicado: (2018)

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
por: Gangadhar, Tara C., et al.
Publicado: (2017)

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)
por: Hodi, F Stephen, et al.
Publicado: (2014)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
por: Dummer, Reinhard, et al.
Publicado: (2014)

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
por: Hamid, Omid, et al.
Publicado: (2021)

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
por: Amin, Asim, et al.
Publicado: (2016)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
por: Ayers, Mark, et al.
Publicado: (2015)

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
por: Long, Georgina V, et al.
Publicado: (2015)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
por: Tan, Irena, et al.
Publicado: (2018)

Infectious Colitis Associated With Ipilimumab Therapy
por: McCutcheon, Jessica L., et al.
Publicado: (2014)

Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices
por: Cowey, C. Lance, et al.
Publicado: (2018)

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7)
por: Puzanov, Igor, et al.
Publicado: (2014)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
por: Karydis, Ioannis, et al.
Publicado: (2016)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
por: Tawbi, Hussein A, et al.
Publicado: (2021)

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
por: Wolchok, Jedd D, et al.
Publicado: (2013)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
por: Minor, David R., et al.
Publicado: (2015)

Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report
por: Porntharukchareon, Thachanun, et al.
Publicado: (2020)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
por: Chesney, Jason A., et al.
Publicado: (2023)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
por: Chesney, Jason A, et al.
Publicado: (2023)

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
por: Bostwick, A Doran, et al.
Publicado: (2015)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
por: Hamid, O, et al.
Publicado: (2019)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2020)

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
por: Bartell, Heddy, et al.
Publicado: (2015)

Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature
por: Gravbrot, Nicholas, et al.
Publicado: (2019)

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
por: Möhn, Nora, et al.
Publicado: (2019)

Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center
por: Vo, Henry Hiep, et al.
Publicado: (2022)

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
por: Long, Georgina V., et al.
Publicado: (2021)

Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab
por: Singh, Abhay, et al.
Publicado: (2020)

Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
por: Puzanov, Igor
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dtdgd5ainpjmhraoqq76rlgsj5